Table 6 – STI Treatment Guidelines
Recommended doses of licensed formulations of hepatitis B vaccines
| Age group (yrs) | Single-antigen vaccine | Combination vaccine | ||||||
|---|---|---|---|---|---|---|---|---|
| Recombivax HB | Engerix-B | Heplisav-B* | Twinrix† | |||||
| Dose (μg)§ | Volume (mL) | Dose (μg)§ | Volume (mL) | Dose (μg)§ | Volume (mL) | Dose (μg)§ | Volume (mL) | |
| Infants (<1) | 5 | 0.5 | 10 | 0.5 | —¶ | —¶ | NA | NA |
| Children (1–10) | 5 | 0.5 | 10 | 0.5 | —¶ | —¶ | NA | NA |
| Adolescents (11–15) | 10** | 1.0 | NA | NA | —¶ | —¶ | NA | NA |
| Adolescents (11–19) | 5 | 0.5 | 10 | 0.5 | —¶ | —¶ | NA | NA |
| Adults (≥18) | —†† | —†† | —†† | —†† | 20* | 0.5 | 20† | 1 |
| Adults (≥20) | 10 | 1 | 20 | 1 | 20† | 0.5 | 20† | 1 |
| Hemodialysis patients and other immunocompromised persons (<20§§) | 5 | 0.5 | 10 | 0.5 | 20 | 0.5 | NA | NA |
| Hemodialysis patients and other immunocompromised persons (≥20) | 40¶¶ | 1 | 40*** | 2.0 | 20 | 0.5 | NA | NA |
Source: Adapted from Schillie S, Vellozzi C, Reingold A, et al. Prevention of hepatitis B virus infection in the United States: recommendations of the Advisory Committee on Immunization Practices. MMWR Recomm Rep 2018;67(No. RR-1).
Abbreviation: NA = not applicable.
* Administered on a 2-dose schedule.
† Combined hepatitis A and B vaccines. This vaccine is recommended for persons aged ≥18 years who are at increased risk for both hepatitis B and hepatitis A virus infections.
§ Recombinant hepatitis B surface antigen protein dose.
¶ Heplisav-B should not be used for vaccination of infants, children, or adolescents because the safety and effectiveness of Heplisav-B has not been established in persons aged <8 years and is not approved for use in these populations.
** Adult formulation administered on a 2-dose schedule.
†† Engerix-B and Recombivax HB are approved for use in persons of all ages.
§§ Higher doses might be more immunogenic; however, no specific recommendations have been made.
¶¶ Dialysis formulation administered on a 3-dose schedule at 0, 1, and 6 months.
*** Two 1.0-mL doses administered at one site, on a 4-dose schedule at 0, 1, 2, and 6 months.